Response to CVD chemotherapy in SDHB-mutated metastatic paraganglioma: case report
Author Information
Author(s): Zhang Chenyan, Wei Yuanfeng, Cheng Ke, Cao Dan
Primary Institution: West China Hospital, Sichuan University, Chengdu, Sichuan, China
Hypothesis
The study aims to contribute additional evidence to the existing knowledge associated with SDHB-mutated paragangliomas.
Conclusion
The patient showed significant tumor shrinkage and complete symptom remission following chemotherapy.
Supporting Evidence
- The patient had a significant tumor shrinkage after two cycles of chemotherapy.
- Complete biochemical response was observed, allowing cessation of symptomatic therapies.
- The progression-free survival with CVD chemotherapy was 24 months.
Takeaway
A man with a rare tumor got better after receiving special chemotherapy, which helped shrink his tumor and stop his symptoms.
Methodology
The patient received cyclophosphamide-vincristine-dacarbazine (CVD) chemotherapy and was monitored through imaging and biochemical tests.
Limitations
The study is based on a single case report, limiting the generalizability of the findings.
Participant Demographics
A 40-year-old male Asian patient.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website